Navigation Links
Clearance of hepatitis C viral infection after liver transplantation

Touching stories of living donor transplantation are continuously happening in hospitals. One of these stories is reported recently in the August 14 issue of the World Journal of Gastroenterology because of its shining significance in hepatology. This article is going to bring comfort to many families.

It is about a desperate patient brought to Dr. Tatsuki Ichikawa in the Nagasaki University Hospital, Japan in 2004. This patient was quite a challenge for Dr Ichikawa. She was 60 years old with liver cirrhosis (LC) and liver cancer caused by hepatitis C virus (HCV); she had been diagnosed diabetic since 1995; and previous chemotherapies aiming to remove cancer did not bring any satisfactory result.

To free the patient from the severely damaged liver, liver transplantation (LT) was considered by Dr. Ichikawa when a loving daughter of the patient decided to donate part of her liver to her mother. However, one possibility that concerned Dr. Ichikawa most was that the explanted liver would get re-infected and progress rapidly to LC, since previous data indicated that complete clearance of HCV is the prerequisite for patients to have a good outcome. To minimize this possibility, patients were traditionally treated with interferon (IFN) and/or ribavirin before LT.

Trying to save the life of the patient, Dr Ichikawa decided to introduce the more powerful medicine, PEGylated IFN, in the treatment before liver transplantation. PEGylation is a chemical modification incurring higher water-solubility and higher stability to the modified polypeptide medicine. Five weeks after the PEG-IFN treatment, HCV antigen was no longer detectable from the patient serum, but HCV-RNA persisted. Even after the long treatment for 18 weeks, HCV RNA was still detectable. Since the complete clearance of HCV RNA seemed impossible, the liver transplantation was performed.

Unexpectedly and excitingly, clearance of HCV RNA was achieved just one month after the successful liver transplantation and HCV was never detected in this patient thereafter. Thus, this is the first reported case in which a complete recovery from HCV infection was achieved after LT, with a patient who was diagnosed positive in HCV-RNA and negative in HCV core antigen before LT. Dr. Ichikawa suggested that the long acting of PEG-IFN might bring good outcome to similar patients awaiting liver transplantation.

This case no doubt brings promising future for many LC patients. Due to the high percentage of HCV infected population in the world and unavailability of commercial vaccine against HCV, the case reported by Dr Ichikawa surely worth the attention of both doctors and common people.

Contact: Lixin Zhu
World Journal of Gastroenterology

Related biology news :

1. Scientists Replicate Hepatitis C Virus in Laboratory
2. Norovirus, AIDS vaccine and Hepatitis Virus
3. Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis
4. UCLA study assesses cost-effectiveness of Hepatitis B drugs
5. Natural Killers Could Lead to New Hepatitis Treatments
6. FDA Approves New Treatment for Chronic Hepatitis B
7. Scalpel-free surgery could reduce risk of HIV and hepatitis exposure for health care workers
8. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
9. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
10. Researchers create infectious hepatitis C virus in a test tube
11. Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied
Post Your Comments:
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court ... issued another key ruling in favor of Crossmatch ... Korean fingerprint scanner company Suprema and its U.S. partner ... 1930, a trade provision that declares it unlawful to ... by infringing two of Crossmatch,s patents, the 5,900,993 patent ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced that Lenovo has selected Synaptics , ... FS4202, for its latest smartphone, the Vibe P1. The ... to unlock the device and provide swift access to ... The feature-rich Natural ID FS4202 sensor solution utilizes AES256-bit ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... JACKSONVILLE, Florida , October 13, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, will be a featured presenting company ... at the Wyndham Grand Hotel in ... --> TapImmune, Inc. (TPIV), a clinical-stage immunotherapy ...
(Date:10/13/2015)... ... October 13, 2015 , ... Clinovo recently appointed Jeff Parr ... company’s fast growing clinical data solutions business. , Jeff Parr has spent the past ... sizes, including Avery Dennison, Thermo Fisher, and Ab Sciex to name a few. ...
(Date:10/13/2015)... the United States , Canada ... of all new cases of kidney cancer.   --> ... and Europe .  PRCC represents about 14% of ... China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison MediPharma ... have completed enrolment in a global Phase II study of savolitinib ...
(Date:10/12/2015)... , Oct. 12, 2015 This report ... which include cell type, products, applications, end-user markets and ... REPORT HIGHLIGHTS The global cell expansion market generated ... expected to reach revenues of $9.7 billion in 2015 ... growth rate (CAGR) of 17.8% from 2015 to 2020. ...
Breaking Biology Technology: